Analysis of histopathologic and molecular pathologic findings in Czech LGMD2A patients

被引:33
|
作者
Hermanová, M
Zapletalová, E
Sedlácková, J
Chrobáková, T
Letocha, O
Kroupová, I
Zámecník, J
Vondrácek, P
Mazanec, R
Maríková, T
Vohánka, S
Fajkusová, L
机构
[1] Univ Hosp Brno, Dept Pathol, Brno 62500, Czech Republic
[2] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Brno 62500, Czech Republic
[3] Masaryk Univ, CS-60177 Brno, Czech Republic
[4] Univ Hosp Motol, Dept Pathol & Mol Med, Prague, Czech Republic
[5] Univ Hosp Brno, Dept Child Neurol, Brno 62500, Czech Republic
[6] Univ Hosp Motol, Dept Neurol, Prague, Czech Republic
[7] Univ Hosp Motol, Inst Biol & Med Genet, Fac Med 2, Prague, Czech Republic
[8] Univ Hosp Brno, Dept Neurol, Brno 62500, Czech Republic
关键词
LGMD2A; muscle biopsy; mutational analysis; neurogenic pattern;
D O I
10.1002/mus.20480
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Limb-girdle muscular dystrophy type 2A (LGMD2A) is an autosomal-recessive disorder characterized by selective atrophy and progressive weakness of proximal girdle muscles. LGMD2A, the most prevalent form of LGMD, is caused by mutations in the CAPN3 gene that encodes the skeletal muscle-specific member of the calpain family, calpain-3 (p94). We examined the histopathologic and molecular pathologic findings in 14 Czech LGMD2A patients. Analysis of the CAPN3 gene was performed at the mRNA level, using reverse transcription-polymerase chain reaction (RT-PCR) and sequencing, and/or DNA level, using PCR and denaturing high-performance liquid chromatography (DHPLC). Our results confirm that mutation 550delA is the most frequent CAPN3 defect in Czech LGMD2A patients (9 alleles of 28). Furthermore, we established that, in a patient with the 550delA/R490W genotype, mRNA carrying frameshift mutation 550delA was not detected, probably due to its degradation by nonsense-mediated mRNA decay. In muscle biopsies of two LGMD2A patients, a neurogenic pattern simulating a neurogenic lesion was observed. Immunoblot analysis revealed the deficiency of p94 in all genetically confirmed cases of LGMD2A, and secondary dysferlin deficiency was demonstrated on muscle membranes in 6 patients using immunofluorescence. Thus, we find a combination of DNA and mRNA mutational analysis to be useful in the diagnosis of LGMD2A. Moreover, our study expands the spectrum of calpainopathies to cases that simulate a neurogenic lesion in muscle biopsies, and the knowledge of possible secondary deficiencies of muscular proteins also contributes to a diagnosis of LGMD2A.
引用
收藏
页码:424 / 432
页数:9
相关论文
共 50 条
  • [1] Analysis of histopathologic and molecular genetic findings in Czech LGMD2A patients
    Hermanova, M
    Fajkusova, L
    Zapletalova, E
    Sedlackova, J
    Vondracek, P
    Zamecnik, J
    NEUROMUSCULAR DISORDERS, 2005, 15 (9-10) : 690 - 690
  • [2] Calpainopathy (LGMD2A) in Croatia: Molecular and haplotype analysis
    Milic, A
    Canki-Klain, N
    CROATIAN MEDICAL JOURNAL, 2005, 46 (04) : 657 - 663
  • [3] Molecular diagnosis in LGMD2A: Mutation analysis or protein testing?
    Fanin, M
    Fulizio, L
    Nascimbeni, AC
    Spinazzi, M
    Piluso, G
    Ventriglia, VM
    Ruzza, G
    Siciliano, G
    Trevisan, CR
    Politano, L
    Nigro, V
    Angelini, C
    HUMAN MUTATION, 2004, 24 (01) : 52 - 62
  • [4] Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome
    Chrobáková, T
    Hermanová, M
    Kroupová, I
    Vondrácek, P
    Maríková, T
    Mazanec, R
    Zámecník, J
    Stanek, J
    Havlová, M
    Fajkusová, L
    NEUROMUSCULAR DISORDERS, 2004, 14 (10) : 659 - 665
  • [5] Molecular-pathologic and genetic diagnostics of limb girdle muscular dystrophy LGMD2A:: presentation of first cases diagnosed in the Czech Republic
    Hermanová, M
    Chrobáková, T
    Fajkusová, L
    Kroupová, I
    Vondrácek, P
    Kren, L
    Mazanec, R
    Zámencník, J
    Maríková, T
    Stanek, J
    Havlová, M
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2004, 67 (06) : 415 - 422
  • [6] Mutation in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome
    Sedláeková, J
    Chrobáková, T
    Hermanová, M
    Kroupová, I
    Vondraèek, P
    Maoíková, T
    Mazanec, R
    Zámeèník, J
    Fajkusova, L
    NEUROMUSCULAR DISORDERS, 2004, 14 (8-9) : 605 - 605
  • [7] Clinical features of LGMD2A in a cohort of Czech patients from Motol University Hospital Prague
    Mazanec, R.
    Potockova, V.
    Stehlkova, K.
    Fajkusova, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 626 - 626
  • [8] Recurrent LGMD2A (calpainopathy) mutations in Brazilian patients.
    Paula, F
    Moreira, ES
    Bernardino, ALF
    Kai, A
    Passos-Bueno, MR
    Veinzof, M
    Zatz, M
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 251 - 251
  • [9] Screening of the CAPN3 gene in patients with possible LGMD2A
    Krahn, M
    Bernard, R
    Pécheux, C
    Hammouda, EH
    Eymard, B
    De Munain, AL
    Cobo, AM
    Romero, N
    Urtizberea, A
    Leturcq, F
    Léevy, N
    CLINICAL GENETICS, 2006, 69 (05) : 444 - 449
  • [10] Immunohistochemical analysis of calpain 3: Advantages and limitations in diagnosing LGMD2A
    Charlton, R.
    Henderson, M.
    Richards, J.
    Hudson, J.
    Bushby, K.
    Barresi, R.
    NEUROMUSCULAR DISORDERS, 2008, 18 (9-10) : 815 - 815